How a naturally occurring protein inspired a next-generation biologic for osteoarthritis.
In the race to develop effective therapies, drug developers often try to outsmart biology. At Cytonics, we took a different approach: we listened to it.
A2M: Nature’s Protease Inhibitor
Alpha-2-Macroglobulin (A2M) is a powerful protein already present in the human body. Its role? To trap and neutralize harmful enzymes—specifically, proteases that, when overactive, degrade cartilage and inflame joints. Think of it as the body’s natural clean-up crew for injured tissues.
In healthy joints, A2M keeps protease activity in check. But in osteoarthritis (OA), the destructive enzymes overwhelm A2M’s defenses. That imbalance leads to chronic inflammation, cartilage loss, and progressive joint degeneration.
This observation raised a compelling question:
What if we could restore that balance—by delivering more A2M, precisely where it’s needed?
The Foundation for a New Therapy
Our journey began with a simple experiment: concentrating A2M from human blood and applying it to protease-rich environments in vitro.
The results were striking: protease activity dropped significantly, suggesting that A2M could directly neutralize the enzymes responsible for joint destruction. This experiment laid the foundation for our first-generation therapy, APIC™, a medical device that isolates and concentrates natural A2M from a patient’s own blood for injection into damaged joints.
To date, over 10,000 patients have been treated with APIC™, and the results speak for themselves: sustained pain relief, improved mobility, and reduced inflammation.
Building on Nature’s Blueprint
While APIC™ proved A2M’s potential, it also revealed its limitations. The natural protein is fragile, patient-derived, and varies in quality. That’s where our second-generation innovation—CYT-108—comes in.
CYT-108 is a recombinant, engineered version of A2M, built for consistency, potency, and enhanced function. By analyzing A2M’s structure and optimizing it for therapeutic use, we created a drug candidate capable of:
- Blocking multiple classes of cartilage-degrading proteases
- Reducing joint inflammation
- Potentially stimulating cartilage regeneration
In preclinical models, CYT-108 demonstrated over 200% greater efficacy in enzyme inhibition compared to natural A2M.
Listening to Biology, Not Chasing Symptoms
Most OA treatments today are designed to mask symptoms: steroids, painkillers, and expensive injectables that wear off in weeks. But CYT-108 is built to intervene at the root cause—the enzymatic imbalance that drives cartilage degradation.
Nature gave us the blueprint. At Cytonics, we’re engineering the upgrade.
Appreciatively,
Joey Bose
President & CEO
Reg A Disclaimer
This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. You may obtain a copy of the offering circular here.
